- Oops!Something went wrong.Please try again later.
Shares of Bristol-Myers Squibb (NYSE:BMY) moved higher by 1.4% in pre-market trading after the company reported Q3 results.
Earnings per share rose 39.32% year over year to $1.63, which beat the estimate of $1.49.
Revenue of $10,540,000,000 up by 75.46% year over year, which beat the estimate of $10,330,000,000.
Bristol-Myers Squibb hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Nov 05, 2020
Time: 08:30 AM
Recent Stock Performance
Company's 52-week high was at $68.34
Company's 52-week low was at $45.76
Price action over last quarter: Up 8.75%
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.